GSK: presents new data for asthma
(CercleFinance.com) - GlaxoSmithKline (GSK) has presented new data on Nucala (mepolizumab) from an interim analysis of REALITI-A, the first prospective global study of biologic therapy in patients with severe eosinophilic asthma.
The results show a significant reduction in exacerbations and use of oral corticosteroids in patients after one year of routine Nucala treatment compared to the previous 12 months.
REALITI-A is expected to be completed in 2021, with its full results published and presented at future scientific meetings.
Christopher Corsico, Senior Vice President Development, GSK, said, "Exacerbations can be devastating for people living with severe eosinophilic asthma. The interim results from REALITI-A continue to demonstrate Nucala effectively reduces exacerbations, this time in a routine care setting. We look forward to sharing the full results from this study after it completes in 2021."
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The results show a significant reduction in exacerbations and use of oral corticosteroids in patients after one year of routine Nucala treatment compared to the previous 12 months.
REALITI-A is expected to be completed in 2021, with its full results published and presented at future scientific meetings.
Christopher Corsico, Senior Vice President Development, GSK, said, "Exacerbations can be devastating for people living with severe eosinophilic asthma. The interim results from REALITI-A continue to demonstrate Nucala effectively reduces exacerbations, this time in a routine care setting. We look forward to sharing the full results from this study after it completes in 2021."
Copyright (c) 2019 CercleFinance.com. All rights reserved.